Pfizer Inc. $PFE Shares Bought by Fifth Third Wealth Advisors LLC

Key Points

• Fifth Third Wealth Advisors LLC increased its stake in Pfizer Inc. by 20.6% during the second quarter, owning 145,041 shares valued at $3,516,000.
• Pfizer reported a 10.3% year-over-year revenue increase to $14.65 billion for the last quarter, exceeding analysts' expectations.
• The company recently declared a quarterly dividend of $0.43 per share, representing a 6.9% yield and a payout ratio of 91.49%.

Fifth Third Wealth Advisors LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 20.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 145,041 shares of the biopharmaceutical company's stock after acquiring an additional 24,756 shares during the period. Fifth Third Wealth Advisors LLC's holdings in Pfizer were worth $3,516,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Brighton Jones LLC grew its position in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its position in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after buying an additional 2,087 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Pfizer by 69.0% during the 1st quarter. GAMMA Investing LLC now owns 63,131 shares of the biopharmaceutical company's stock valued at $1,600,000 after buying an additional 25,785 shares during the last quarter. Focus Financial Network Inc. grew its position in shares of Pfizer by 1.3% during the 1st quarter. Focus Financial Network Inc. now owns 47,522 shares of the biopharmaceutical company's stock valued at $1,204,000 after buying an additional 607 shares during the last quarter. Finally, Simon Quick Advisors LLC grew its position in shares of Pfizer by 15.5% during the 1st quarter. Simon Quick Advisors LLC now owns 27,075 shares of the biopharmaceutical company's stock valued at $686,000 after buying an additional 3,627 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Down 1.7%

Shares of NYSE:PFE opened at $24.81 on Friday. The company has a 50 day moving average of $24.86 and a 200-day moving average of $24.14. The firm has a market cap of $141.03 billion, a P/E ratio of 13.19, a P/E/G ratio of 0.83 and a beta of 0.55. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $29.82. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the firm earned $0.60 EPS. The company's quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer's payout ratio is currently 91.49%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on PFE shares. Wall Street Zen downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, September 28th. Weiss Ratings restated a "hold (c-)" rating on shares of Pfizer in a research note on Wednesday. Morgan Stanley cut their price target on Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a report on Friday. Citigroup lifted their price target on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Finally, Bank of America lifted their price target on Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a report on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $28.35.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.